Free Trial
NASDAQ:PROK

ProKidney Q2 2023 Earnings Report

ProKidney logo
$0.79 -0.01 (-0.63%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$0.81 +0.02 (+2.29%)
As of 04/17/2025 06:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ProKidney EPS Results

Actual EPS
-$0.14
Consensus EPS
-$0.41
Beat/Miss
Beat by +$0.27
One Year Ago EPS
N/A

ProKidney Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ProKidney Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Thursday, August 10, 2023
Conference Call Time
8:00AM ET

Upcoming Earnings

ProKidney's Q1 2025 earnings is scheduled for Friday, May 9, 2025, with a conference call scheduled at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

ProKidney Earnings Headlines

ProKidney Corp.
Claim Your FREE Protection Guide
In the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code... And since then, "in the know" patriots have quietly used this same "Trump loophole" to shield their life savings from the economic chaos. But with Trump now forcefully bringing back millions of manufacturing jobs from Mexico, China, and the entire BRICS anti-dollar coalition...
ProKidney reports FY24 EPS (62c), consensus (59c)
See More ProKidney Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ProKidney? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ProKidney and other key companies, straight to your email.

About ProKidney

ProKidney (NASDAQ:PROK), a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

View ProKidney Profile

More Earnings Resources from MarketBeat